Curtanapharma
Austin, US · 1 known investors
Curtana Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule inhibitors for brain cancer, particularly pediatric high-grade glioma. The company focuses on improving therapeutic outcomes for patients with aggressive brain cancers.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Curtanapharma do?
- Curtana Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule inhibitors for brain cancer, particularly pediatric high-grade glioma. The company focuses on improving therapeutic outcomes for patients with aggressive brain cancers.
- Who are Curtanapharma's investors?
- Curtanapharma's investors include Thynk Capital.
- Where is Curtanapharma headquartered?
- Curtanapharma is headquartered in Austin, US.